Algernon Pharmaceuticals receives notice of allowance from EPO for Repirinast

Algernon Pharmaceuticals (AGNPF) announces that it has received a notice of allowance from the European Patent Office, EPO, for patent application 19827430.0 for its lead chronic kidney disease program drug NP-251. The invention claims the use of Repirinast, either alone or in combination with telmisartan, for the treatment or prophylaxis of renal fibrosis or kidney disease. The base claims of the patent will be valid through 2038, excluding any patent term adjustments or extensions which may provide additional protection. The Company has previously announced the allowance of this patent application in the U.S., Japan and China. The patent is currently pending in Canada.